Analyzing...
Loading company...
Onesource Specialty Pharma Ltd develops and distributes niche pharmaceutical products, catering to specialized therapeutic areas. The company integrates research, regulatory compliance, and supply chain management for effective healthcare delivery.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹1,422 Cr revenue.
COGS 31.3%, employees 17.0%.
“reiterate our FY twenty twenty eight guidance, which we have given of becoming a $400,000,000 revenue company organically.”
“singular guidance that we have provided”
“Firstly, I would like everybody to draw my attention, sorry, draw your attention to my Q4 FY 'twenty five commentary where I highlighted that FY 'twenty six is a transitionary year, where our primary ”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | -1.3%▼ | 10.3% |
| ROCE | 0.4%▼ | 13.7% |
| Net Margin | -5.1%▼ | 7.6% |
| EBITDA Margin | 21.5%▲ | 15.4% |
| Debt To Equity | 0.22x▲ | 0.15x |
| (₹ Cr) | TTM | FY2025 |
|---|---|---|
| Revenue | ₹1,543 Cr +6.8% | ₹1,445 Cr |
| Other Income | ₹14 Cr -22.4% | ₹17 Cr |
| Total Income | ₹1,557 Cr +6.5% | ₹1,462 Cr |
| COGS | ₹496 Cr +14.1% | ₹435 Cr |
| ₹1,613 Cr +13.7% | ₹1,419 Cr | |
| Profit Before Tax | (₹67 Cr) -0.3% | (₹67 Cr) |
| Exceptional Items | (₹11 Cr) +89.8% | (₹111 Cr) |
| (₹19 Cr) +62.5% | (₹50 Cr) | |
| Net Profit | (₹49 Cr) -181.3% | (₹17 Cr) |
| Profit (Owners) | (₹49 Cr) -170.5% | (₹18 Cr) |
| Other Comprehensive Income | ₹17 Cr ↑ Recovery | (₹3 Cr) |
| EPS | (₹4.24) | (₹1.57) |
| Diluted Shares | ₹11 Cr | ₹11 Cr |
| Profit Loss From Discontinued Operations After Tax | ₹0.00 Cr +100.0% | (₹0.69 Cr) |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
OneSource Specialty Pharma Limited has informed the Exchange about Earnings Call Transcript dated July 25, 2026
Onesource Specialty Pharma Limited has informed the Exchange about change in Management
Onesource Specialty Pharma Limited has informed the Exchange about Copy of Newspaper Publication
OneSource Specialty Pharma Limited has informed the Exchange about Link of Recording
Onesource Specialty Pharma Limited has informed the Exchange regarding 'Allotment of ESOPs'.
Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated July 24, 2026, titled "OneSource announces strong Q1FY27 results Revenue up 37% YoY and EBITDA up 39% YoY".
Onesource Specialty Pharma Limited has informed the Exchange about change in Management of the Company
Onesource Specialty Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Onesource Specialty Pharma Limited has informed the Exchange about Schedule of meet on July 25, 2026
Onesource Specialty Pharma Limited has informed the Exchange regarding 'OneSource Specialty Pharma and Formycon AG announceStrategic Manufacturing Partnership for Biosimilars'.
Onesource Specialty Pharma Limited has informed the Exchange about allotment of ESOPs
Tenshi Pharmaceuticals Private Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Ta...
In furtherance to the clarification sought by the exchange with regard to the OCR readable format of the financial results, Onesource Specialty Pharma Limited has submitted the OCR Readable financial ...
In furtherance to the intimation made on May 13, 2026, w.r.t the resignation of the SMP, Onesource Specialty Pharma Limited has informed the Exchange regarding resignation document of SMP.
Onesource Specialty Pharma Limited has informed the Exchange regarding the receipt of in-principle approval from the Government of Karnataka for the application submittedby the Company for its Unit II...
No dividend history available for this company.